Bioptix Inc : Bioptix announces streamlining of workforce . Company is reviewing possible strategic alternatives for business . Bioptix Inc - will terminate certain employees associated with september 2016 acquisition of its subsidiary, bioptix diagnostics . Bioptix Inc - commenced terminations on January 16, 2017 and terminations are expected to be completed within 30 days .Company may pay severance benefits in certain circumstances of up to one month base salary.
Agenus Inc :Files for offering of up to 157,513 shares of co's common stock by the selling stockholder - SEC filing.
Affimed NV : Affimed announces pricing of public offering of common stock .Says public offering of 10 million common shares priced at $1.80 per share.
Stemline Therapeutics Inc : Stemline Therapeutics prices $45 million public offering of common stock . Says public offering of 4.50 million common shares priced at $10.00per share .Offering is expected to close on January 25, 2017.
OncoMed Pharmaceuticals Inc :OncoMed initiates enrollment of phase 1B clinical trial of Brontictuzumab for the treatment of metastatic colorectal cancer patients.
Minerva Neurosciences Inc :Additional data analyses from phase IIb trial of MIN-101 in schizophrenia underscore benefit in multiple measurements of cognitive function.
Guangzhou Boji Medical and Biotechnological Co Ltd <300404.SZ> : Says it plans to set up a clinical research JV with partner, a Jiangxi-based pharma .JV will be capitalized at 20 million yuan and co will hold a 51 percent stake in it.
BB Biotech AG : Portfolio performs well in in the volatile fourth quarter of 2016 . 5% dividend yield maintained - BB Biotech management is very confident about sector's prospects in 2017 . A proposed dividend of 2.75 Swiss francs ($2.74)per share . 2017 will bring an acceleration of important product approvals and milestone read-for industry and bb biotech's portfolio . Consolidated but not yet audited Q4 data for BB Biotech record a net loss of 24 mln Swiss francs versus last year's quarter gain of 511 mln Swiss francs .Consolidated but not yet audited full year 2016 data, showed a net loss of 802 mln Swiss francs versus a full year net profit of 653 mln Swiss francs for 2015..
Pluristem Therapeutics Inc : Pluristem announces bought deal offering . Pluristem Therapeutics Inc says to sell 8.2 million shares of common stock of company, at a price to public of US$1.225 per share .Pluristem Therapeutics - Use proceeds of offering for research, product development activities, clinical trial activities, investment in capital equipment.